Literature DB >> 12731674

The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas.

Tatsuharu Ohno1, Yasunori Ueda, Ken-ichi Nagai, Takayuki Takahashi, Yoshiteru Konaka, Teruyuki Takamatsu, Takayo Suzuki, Masataka Sasada, Takashi Uchiyama.   

Abstract

To elucidate the differences in pathogenesis between lymphoma-associated hemophagocytic syndromes (LAHS) of the T-cell/ natural killer cell (T/NK) and B-cell (B) types, we comparatively analyzed the clinical features and serum cytokine profiles of 33 patients with LAHS registered in the Kyoto University Hematology/Oncology Study Group. The serum cytokine levels of each patient group (B-LAHS versus T/NK-LAHS) were expressed as the ratio of the median to the upper normal values of the respective cytokines and were as follows: 19.05 versus 13.99 for soluble interleukin 2 (IL-2) receptor, 0.67 versus 0.67 for granulocyte-macrophage colony-stimulating factor (GM-CSF), 0.64 versus 1.26 for G-CSF, 5.70 versus 3.61 for M-CSF, 1.54 versus 3.39 for interferon gamma (IFN-gamma), 13.17 versus 1.17 for IL-6, 6.88 versus 1.58 for tumor necrosis factor alpha (TNF-alpha), 0.71 versus 0.41 for IL-1beta, 1.99 versus 0.21 for IL-12, and 105.32 versus 29.65 for IL-10. The serum levels of IL-6, TNF-alpha, and IL-10 were significantly higher in the B-LAHS group, whereas those of IFN-y were significantly lower. These differences between the 2 groups may reflect a difference in the pathogenesis Higher serum levels of IL-6, TNF-alpha, and IL-10 may be derived at least partly from neoplastic B-cells themselves In addition, the extremely high serum levels of IL-10 suggest that a compensatory anti-inflammatory process may operate in both groups and give rise to a profound immunosuppressive state and a poor outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12731674     DOI: 10.1007/bf02983788

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  56 in total

1.  Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma.

Authors:  S Imashuku; S Hibi; Y Tabata; S Todo
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

2.  Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma.

Authors:  T Ohno; N Miyake; S Hada; Y Hirose; A Imura; T Hori; T Uchiyama; T Saiga; T Mizumoto; H Furukawa
Journal:  Cancer       Date:  1998-05-15       Impact factor: 6.860

3.  Malignant histiocytosis. A reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies.

Authors:  M S Wilson; L M Weiss; K C Gatter; D Y Mason; R F Dorfman; R A Warnke
Journal:  Cancer       Date:  1990-08-01       Impact factor: 6.860

4.  Systemic inflammatory response syndrome in intravascular lymphomatosis.

Authors:  M Ip; K W Chan; I K Chan
Journal:  Intensive Care Med       Date:  1997-07       Impact factor: 17.440

5.  Bone marrow findings in malignant histiocytosis and/or malignant lymphoma with concurrent hemophagocytic syndrome.

Authors:  M Takeshita; M Kikuchi; K Ohshima; K Nibu; J Suzumiya; S Hisano; Y Miyamoto; T Okamura
Journal:  Leuk Lymphoma       Date:  1993-12

6.  Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  H Kawaguchi; T Miyashita; H Herbst; G Niedobitek; M Asada; M Tsuchida; R Hanada; A Kinoshita; M Sakurai; N Kobayashi
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

7.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.

Authors:  K Kawa-Ha; S Ishihara; T Ninomiya; K Yumura-Yagi; J Hara; F Murayama; A Tawa; K Hirai
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  Epstein-Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis.

Authors:  I J Su; Y H Hsu; M T Lin; A L Cheng; C H Wang; L M Weiss
Journal:  Cancer       Date:  1993-09-15       Impact factor: 6.860

9.  Fatal Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  H Kikuta; Y Sakiyama; S Matsumoto; T Oh-Ishi; T Nakano; T Nagashima; T Oka; T Hironaka; K Hirai
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

10.  Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5.

Authors:  M S Loughnan; C J Sanderson; G J Nossal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  14 in total

1.  Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis.

Authors:  Jun An; Hiroshi Fujiwara; Koichiro Suemori; Toshiyuki Niiya; Taichi Azuma; Kazushi Tanimoto; Toshiki Ochi; Yoshiki Akatsuka; Junichi Mineno; Hidetoshi Ozawa; Fumihiko Ishikawa; Kiyotaka Kuzushima; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2011-01-13       Impact factor: 2.490

2.  Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.

Authors:  M Gupta; M Stenson; M O'Byrne; M J Maurer; T Habermann; J R Cerhan; G W Weiner; T E Witzig
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

3.  Lymphoma associated hemophagocytic syndrome: A single-center retrospective study.

Authors:  Yu Chang; Meng Cui; Xiaorui Fu; Lijuan Han; Lei Zhang; Ling Li; Xin Li; Zhenchang Sun; Jingjing Wu; Xudong Zhang; Zhaoming Li; Feifei Nan; Jiaqin Yan; Guangyao Sheng; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

4.  Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.

Authors:  Takeshi Sano; Hisashi Sakai; Kengo Takimoto; Hitoshi Ohno
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

5.  Murine model of primary intraocular lymphoma.

Authors:  Chi-Chao Chan; Maria Fischette; DeFen Shen; Sankaranarayana P Mahesh; Robert B Nussenblatt; Jacob Hochman
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-02       Impact factor: 4.799

6.  Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.

Authors:  Tatsuharu Ohno; Takashi Sakamoto; Chisaki Mizumoto; Takashi Miyoshi; Maki Ueda; Tomoharu Takeoka; Kouhei Yamashita; Terutoshi Hishita; Shigefusa Hada
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

7.  Nationwide survey of hemophagocytic lymphohistiocytosis in Japan.

Authors:  Eiichi Ishii; Shouichi Ohga; Shinsaku Imashuku; Masaki Yasukawa; Hiroyuki Tsuda; Ikuo Miura; Ken Yamamoto; Hisanori Horiuchi; Kenzo Takada; Koichi Ohshima; Shigeo Nakamura; Naoko Kinukawa; Kazuo Oshimi; Keisei Kawa
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

8.  An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review.

Authors:  Sih-Han Liao; Yin-Kai Chen; Shan-Chi Yu; Ming-Shiang Wu; Hsiu-Po Wang; Ping-Huei Tseng
Journal:  SAGE Open Med Case Rep       Date:  2017-05-26

9.  Natural killer/T-cell lymphoma with concomitant syndrome of inappropriate antidiuretic hormone secretion: A case report and review of literature.

Authors:  Quan-Bo Liu; Rui Zheng
Journal:  World J Clin Cases       Date:  2018-11-06       Impact factor: 1.337

10.  IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome.

Authors:  Hayato Maruoka; Daichi Inoue; Yoko Takiuchi; Seiji Nagano; Hiroshi Arima; Sumie Tabata; Akiko Matsushita; Takayuki Ishikawa; Tatsuo Oita; Takayuki Takahashi
Journal:  Ann Hematol       Date:  2013-08-25       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.